Clients

Retrophin, Inc.

Company Snapshot: Retrophin, Inc.

RTRX
Last Change Volume High Low

Company Overview

Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, New York-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin has begun enrollment in a potentially pivotal Phase 2 clinical trial of its lead compound, sparsentan, for FSGS. The Company also intends to reintroduce Syntocinon Nasal Spray (oxytocin) in the U.S. to assist initial postpartum milk ejection and also initiate clinical trials for the drug as a potential treatment for schizophrenia and autism. Retrophin plans to initiate a Phase 1 pharmacokinetic trial of RE-034, an ACTH analog, in the first half of 2014.

Client News

  1. Feb 19 2020 Retrophin to Present at Upcoming Investor Conferences
  2. Feb 13 2020 Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  3. Feb 10 2020 Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
  4. Jan 13 2020 Retrophin Provides Corporate Update and 2020 Outlook